MPR Weekly Dose Podcast
Approvals for relapsed or refractory multiple myeloma, non-radiographic axial spondyloarthritis, and unresectable hepatocellular carcinoma; advisory committee takes vote on potential treatment for anemia of chronic kidney disease; and an oral formulation of pulmonary arterial hypertension treatment.
Tadliq is a PDE5 inhibitor indicated for the treatment of pulmonary arterial hypertension (WHO Group 1) to improve exercise ability.
Researchers studied the changes of pulmonary artery systolic pressure among patients with interstitial lung disease associated with systemic sclerosis receiving rituximab therapy.
Drugs in the Pipeline
The primary endpoint of the study was exercise capacity, as measured by the change from baseline in 6-minute walk distance at 24 weeks.
By identifying existing medications that may be repurposed for dementia, clinicians may be able to provide faster treatment for those in need.
Observational study findings highlight a "persistent and marked" association between hypertension and risk for severe COVID-19, even among fully vaccinated patients, according to investigators.
Tyvaso DPI is a drug-device combination therapy that consists of a dry powder formulation of treprostinil and a small, portable, dry powder inhaler.
For COPD, can electronic health record data predict 90-day post hospitalization mortality — and thereby serve as a risk stratification tool?
The approval was based on data from a phase 3 trial that evaluated the efficacy and safety of Fintepla in 263 patients aged 2 to 35 years with LGS.
Osteoarthritis is the leading form of arthritis and growing. With people living longer, by 2030 osteoarthritis is expected to become the single greatest cause of disability globally.